Pulike Biological Engineering, Inc. (603566.SS) engages primarily in the research, development, production and sale of veterinary biological products and drugs; its core offerings encompass vaccines, antibodies and medicines for swine and poultry, alongside disinfectants, chemical preparations and traditional Chinese veterinary medicines; the company further provides vaccines and pharmaceuticals for ruminants including cattle and sheep, as well as for pets, with specific products such as porcine circovirus vaccines, mycoplasma vaccines, swine foot-and-mouth disease vaccines, new-branch-stream trivalent inactivated vaccines, new-branch-reduce-stream quadrivalent inactivated vaccines, chicken infectious bursal disease refined egg yolk antibodies and duck viral hepatitis refined egg yolk antibodies. Founded in 1995 and headquartered in Luoyang, Henan province, China, Pulike Biological Engineering, Inc. operates as a state-level high-tech enterprise with comprehensive strength ranking at the industry forefront; it maintains seven subsidiaries focused on vaccines, chemicals and pets, plus two shareholding companies in vaccines and testing, serving primarily the domestic Chinese animal health market while pursuing international expansion through the Belt and Road initiative. In recent developments, the company anticipates receiving CNY 900 million in funding from a group of investors, bolstering its research and development efforts where it invests over 10% of revenues—equivalent to $178 million in 2022—across more than 150 products produced via six GMP facilities and 50 product lines employing over 1,700 staff including 200 in R&D.